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The discovery that cyclin-dependent kinases (Cdks)
orchestrate key cell-cycle transitions in all eucaryotes [1]
was recognized by the 2001 Nobel Prize in Physiology or
Medicine, awarded to Leland Hartwell, Paul Nurse, and
Tim Hunt. The defining feature of the cyclins is that their
abundance fluctuates during the cell cycle, modulating
Cdk activity and driving cell-cycle progression. Important
information continues to emerge on the role of cyclins in
breast cancer. Shortly after their identification in mammals,
it was found that cyclin genes were overexpressed and
amplified in a fraction of breast cancers, providing the first
evidence that cyclin deregulation, in particular increased
transcription, may promote this disease [2].
The present commentary focuses on a recent publication
from Steve Reed’s laboratory that implicates defective
cyclin proteolysis as an alternative mechanism of cyclin
overexpression in breast cancer [3].
Evidence for involvement of cyclin D in breast cancer has
been particularly strong. Cyclin D gene amplification was
readily detected in breast cancers [4]. Moreover, cyclin
D1 overexpression in breast epithelium predisposes to
neoplasia in transgenic mice [5]. Conversely, germline
deletion of cyclin D1 prevents normal proliferation of the
breast epithelium during lactation [6,7] and protects
against breast neoplasia [8].
What about cyclin E, the other major class of cyclins that
promote entry into the mammalian cell cycle? In vitro
experiments have demonstrated that cyclin E overexpres-
sion can mediate genetic instability as well, a factor that
can accelerate tumorigenesis [9]. Transgenic experiments
in the mouse have confirmed that cyclin E overexpression
can induce mammary gland hyperplasia and cancer [10].
In comparison with normal human breast tissues and cul-
tured cells, many human breast cancers display high-level
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expression of cyclin E but also elevations in other markers of
cell proliferation, such as Ki67 [2,11]. In these tumors, it is
difficult to distinguish whether the observed cyclin E expres-
sion is a primary or secondary event in cell proliferation. In
other tumors, cyclin E expression is high relative to the
proliferative index of the tumor, more suggestive of primary
cyclin deregulation [11]. The notion that cyclin E over-
expression plays a significant role in breast cancer is
further supported by evidence that high expression levels
detected by immunohistochemistry in primary tumors
predict poor outcomes [12]. Nonetheless, amplification of
cyclin E genes has been found only rarely in breast
cancers, leaving the mechanism(s) and specificity of the
observed cyclin E expression in doubt [4].
Dissecting cyclin E regulation in yeast
Previous work by the Reed laboratory and others revealed
that cyclin E degradation is fostered by Cdk phosphory-
lation on a threonine residue at position 380 of the primary
sequence [13,14]. Even though yeast do not possess a
true cyclin E homolog, degradation of human cyclin E in
yeast is also fostered by Cdk phosphorylation on Thr380,
consistent with the remarkable conservation of key cell-
cycle paradigms and proteins across eucaryotes.
Strohmaier et al. took advantage of the facile genetic analy-
ses that can be performed in yeast to identify proteins
involved in cyclin E degradation. Their results implicated
Skp1/Cul1/F-box (SCF) complexes and, in particular, the
substrate targeting protein Cdc4 in cyclin E proteolysis in
yeast. SCF complexes are well-known mediators of protein
degradation, directing specific substrates to the 26 S
proteosome by addition of chains of ubiquitin, a small
protein added covalently to lysine residues on the target
[15–17]. A second phosphorylation on cyclin E, at Thr62,
was shown to facilitate cyclin E degradation. The use of
dual phosphorylation sites is consistent with recent
evidence that efficient recognition by Cdc4 can be spurred
by multisite phosphorylation of target proteins [18]. Fur-
thermore, the sequences surrounding Thr380 and Thr62
are good matches to the loose consensus sequence for
Cdc4 binding defined in an independent study [14].
Strohmaier  et al. then identified in Genbank a human
expressed sequence encoding a protein homologous to
Cdc4 (hCdc4) [3]. The hCdc4 cDNA was shown to par-
tially rescue the cdc4 phenotype in yeast. hCdc4 was
found to bind cyclin E, in a manner facilitated by phospho-
rylation of the latter protein. Overexpression of hCdc4 in
human cells reduced the half-life of cyclin E. Conversely,
overexpression of a mutant hCdc4 extended the cyclin E
half-life. Finally, hCdc4 immunoprecipitates could mediate
ubiquitination of cyclin E in a cell-free extract.
Similar results were reported in an elegant study by
Elledge and coworkers [19], in which the hCdc4 protein is
termed SCFFbw7. This nomenclature highlights the pres-
ence in the primary sequence of an ‘F-box’, which marks
the protein as a specificity factor for SCF complexes, and
a WD (tryptophan–aspartic acid) repeat, a motif impli-
cated in protein recognition [20,21].
The Reed group then tested the notion that mutations in
hCdc4 might contribute to upregulation of cyclin E in
breast cancer. Of eight randomly chosen breast cancer
cell lines, two showed high levels of cyclin E protein
without a corresponding elevation in cyclin E mRNA, by
comparison with an immortalized line derived from normal
breast. hCdc4 mRNA from one of the two malignant cell
lines, SUM149PT, migrated aberrantly through an agarose
gel. Immunoreactive hCdc4 could not be detected in this
cell line, and the cyclin E half-life was extended in compar-
ison with that observed in the normal breast cell line. The
hCdc4 mRNA from SUM149PT cells was sequenced,
revealing a truncating mutation. Southern blotting con-
firmed loss of the normal hCdc4 allele.
These data are thus consistent with the notion that
hCdc4 may have suppressed the growth of the
SUM149PT cell of origin, providing a selective advantage
to cells that inactivated both hCdc4 alleles. The other
breast cancer cell line with high levels of cyclin E protein
relative to its mRNA presumably may harbor another
defect in cyclin E degradation.
Whether hCdc4 inactivation in the SUM149PT cell line
occurred during growth of the tumor in vivo or during
establishment of the cell line remains obscure. However,
compelling evidence that loss of Cdc4 can spur cell prolif-
eration in vivo comes from the companion paper [22]. A
mutation in a homologous Drosophila gene, dubbed
Archipelago (Ago), was identified in a screen for mutations
that induced hyperproliferation in the retina. Consistent
with the yeast and human cell data, Ago mutants
displayed elevated cyclin E levels and the mutant Ago
proteins showed reduced affinity for cyclin E in vitro.
Cdc4 has been implicated in the degradation of several
targets in yeast [17]. Hence, whether upregulation of
cyclin E underlies the increased proliferation in Ago
mutants cannot be known for certain from these data.
Genetic crosses to mutants with reduced cyclin E expres-
sion, however, ameliorated the retinal phenotype of Ago
mutants, consistent with the notion that cyclin E is a key
target [22]. Three of 10 ovarian cancer cell lines examined
in this study were found to have mutations in the human
Ago homolog (identical to hCd4/SCFFbw7). On the con-
trary, no mutations were found in this gene in 17 breast
cancer cell lines and in nine primary breast tumors. One
ovarian cell line is homozygous for an early truncating
mutation and very probably is null for hCdc4 function. The
other two mutations in the ovarian cell lines were hetero-147
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zygous missense (single amino acid substitution) muta-
tions, leaving doubt as to whether they inactivated hCdc4
function. However, both mutations alter residues identified
independently as being critical for cyclin E binding [19].
Moreover, Drosophila expressing dacapo, an inhibitor of
cyclin E-associated kinase activity, in the retina displayed
greater retinal cell proliferation when simultaneously
heterozygous for Ago. This implies that Cdc4 function may
be haploinsufficient (limiting in the heterozygous state), at
least in some settings.
These studies thus provide convincing evidence that Cdc4
is a rate-limiting mediator of cyclin E degradation. More-
over, mutations in Cdc4 can confer enhanced cell prolifera-
tion in Drosophila and are found in a fraction of ovarian and
breast cancer cell lines. These findings have built a strong
provisional case that hCdc4 is a tumor suppressor protein.
Definitive evidence would be in hand if restoration of wild-
type hCdc4 in cell lines that harbor hCdc4 mutations
inhibits their proliferation and tumorigenicity, if hCdc4
mutations are identified in primary tumors and/or human
familial cancer pedigrees, and if mice with engineered
Cdc4 mutations are prone to tumor formation.
Conclusion
Part of the complexity of understanding cell-cycle deregu-
lation in cancer has been the observation that specific
abnormalities, such as cyclin gene amplification, have
been found in only a fraction of tumors of a particular type.
In some cases, this complexity has given way to simplicity
with the realization that certain key cell-cycle pathways are
essentially uniformly deregulated in some cancer types,
but by alternative mechanisms (see [23]).
Strohmaier et al. provide strong evidence that abrogation
of hCdc4-mediated degradation of cyclin E, and perhaps
other targets, contributes to development of some breast
cancers, underscoring the important role played by Cdk
deregulation in this tumor type. One lesson thus emerging
from the work by Strohmaier et al. is that, although disrup-
tion of cyclin degradation may be present in only a small
fraction of breast tumors, deregulation of Cdk activity (or a
critical target of Cdks) may yet prove essential for breast
tumorigenesis. Inactivation of retinoblastoma family pro-
teins, mediated by both cyclin D and cyclin E, might be the
common denominator [1].
Further work will establish definitively whether hCdc4 is
indeed a tumor suppressor and whether cyclin E overex-
pression contributes to neoplasia primarily by accelerating
S phase entry per se, by engendering genetic instability,
and/or by other mechanisms (see [24]). If cyclin E overex-
pression remains critical for growth of established tumors,
then cyclin E function may be a good target for
chemotherapeutic drug development. Efforts to develop
such drugs are ongoing [25].
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